

# **Nitric Oxide**

## **Therapeutics, Markets and Companies**

**By**

**Prof. K. K. Jain**  
MD, FRACS, FFPM  
**Jain PharmaBiotech**  
**Basel, Switzerland**

**November 2021**

**A Jain PharmaBiotech Report**

## AUTHOR'S BIOGRAPHY

Professor K. K. Jain is a neurologist/neurosurgeon with specialist qualifications including Fellowships of the Royal Colleges of Surgeons in Australia and Canada. He has trained, practiced, and held academic positions in several countries including Switzerland, India, Iran, Germany, Canada, and USA. After retirement from neurosurgery, Prof. Jain remains a consultant in neurology. He is also working in the biotechnology/biopharmaceuticals industry and is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians of UK. Currently, he is the CEO of Jain PharmaBiotech.

Prof. Jain's 492 publications include 35 books (6 as editor + 29 as author) and 50 special reports, which have covered important areas in biotechnology, gene therapy and biopharmaceuticals. Books relevant to biotechnology and pharmaceuticals include "Role of Nanobiotechnology in Molecular Diagnostics" (2006), "Handbook of Nanomedicine" (Humana/Springer 2008; Chinese edition, Peking University Press 2011, 2<sup>nd</sup> ed Springer 2012, 3<sup>rd</sup> ed 2017), "Textbook of Personalized Medicine (Springer 2009; Japanese ed 2012; 2<sup>nd</sup> ed Springer 2015, 3<sup>rd</sup> ed 2021), "Handbook of Biomarkers" (Springer 2010; Chinese edition by Chemical Industry Press 2016, 2<sup>nd</sup> edition Springer 2017), "Handbook of Neuroprotection" (Springer 2011, 2<sup>nd</sup> ed 2019), "Drug-induced Neurological Disorders", 4<sup>th</sup> ed, Springer 2021), "Applications of Biotechnology in Cardiovascular Therapeutics" (Springer 2011), "Applications of Biotechnology in Neurology" (Springer 2013), and "Applications of Biotechnology in Oncology" (Springer 2014). He has edited "Drug Delivery to the Central Nervous System" (Humana/Springer 2010), "Drug Delivery Systems", 3<sup>rd</sup> edn (Springer 2019) and "Applied Neurogenomics" (Springer 2015). He has also written a "Textbook of Gene Therapy", which was the first book on this subject to be translated into the Chinese language. A book on gene therapy companies was published in 2000 by John Wiley & Sons. Updated material from both these books have been included in 2021 edition of a special report on Gene Therapy published by Jain PharmaBiotech Publications. Some of these books contain sections on nitric oxide. Currently, he is writing "The Handbook of Alzheimer Disease" to be published by Springer in 2022.

**November 2021 (first edition published in 2002)**  
**Copyright © 2021 by**

**Jain PharmaBiotech**  
**Bläsiring 7**  
**CH-4057 Basel**  
**Switzerland**

**Tel & Fax: +4161-6924461**  
**Email: [info@pharmabiotech.ch](mailto:info@pharmabiotech.ch)**  
**Web site: <http://pharmabiotech.ch/>**

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, or otherwise without the prior written permission of the Publisher. This report may not be lent, resold, or otherwise traded in any manner without the consent of the Publisher. While all reasonable steps have been taken to ensure the accuracy of the information presented, the Publisher cannot accept responsibility for inadvertent errors or omissions.

# TABLE OF CONTENTS

<b>0. Executive Summary .....</b>	<b>12</b>
<b>1. Introduction .....</b>	<b>14</b>
<b>Role of nitric oxide in atmosphere and biology .....</b>	<b>14</b>
<b>Historical aspects .....</b>	<b>14</b>
<b>Free radicals .....</b>	<b>15</b>
Nitrogen cycle and NO .....	16
Role of NO in biology and medicine .....	17
<b>Nitric oxide synthase .....</b>	<b>17</b>
Structure and function NOS .....	18
Inducible nitric oxide synthase .....	19
<i>iNOS gene</i> .....	19
<i>Regulation of iNOS</i> .....	20
Regulation of endothelial nitric oxide synthase .....	20
<i>Interaction between eNOS and other proteins</i> .....	20
<i>Tetrahydrobiopterin</i> .....	21
<i>eNOS gene</i> .....	22
<b>NOS-independent NO generation and circulation .....</b>	<b>22</b>
Entero-salivary circulation of nitrate .....	22
<b>Methods of study of NO and NOS .....</b>	<b>23</b>
Colorimetric determination of NO <sub>2</sub> <sup>-</sup> using the Greiss reagent .....	23
Chemiluminescence .....	24
High performance liquid chromatography .....	24
Bioimaging of NO .....	24
DNA-based fluorescent NOS2 probes .....	25
Electrochemical methods using amperometry .....	25
Method using micro ion electrodes .....	25
Metabolomics approach to study of NO metabolism .....	26
<b>2. Nitric Oxide Pathways .....</b>	<b>28</b>
<b>Introduction .....</b>	<b>28</b>
<b>Mechanisms of action of NO .....</b>	<b>29</b>
NO-cGMP pathway .....	29
Nitrate-nitrite-NO pathway .....	30
Soluble guanylyl cyclase as the NO receptor .....	30
<b>Oxidative stress pathways .....</b>	<b>30</b>
NO and oxidative stress .....	31
Oxidative stress and the NO-cyclic GMP signal transduction pathway .....	31
NO and platelets .....	33
Mitochondrial NO-cytochrome c oxidase signaling pathway .....	33
Nitric oxide and cytochrome c oxidase .....	34
Dual role of NO as a free radical and a scavenger .....	35
<b>NO and carbon monoxide .....</b>	<b>35</b>
<b>NO signaling and apoptosis .....</b>	<b>36</b>
<b>3. Role of NO in Physiology .....</b>	<b>38</b>
<b>Role of NO in homeostasis .....</b>	<b>38</b>
<b>Role of NO in adaptation to high altitude .....</b>	<b>38</b>
<b>NO as a biomarker .....</b>	<b>39</b>
<b>Functions of NO in various systems of the body .....</b>	<b>39</b>
NO and proteins .....	40
<i>A proteomic method for identification of cysteine S-nitrosylation sites</i> .....	40
<i>Protein S-nitrosylation and intracellular transport processes</i> .....	40
<i>Cellular inactivation NO by iNOS aggresome formation</i> .....	40
NO and mitochondria .....	41
<i>Mitochondrial permeability and reperfusion injury</i> .....	42
Endocrine role of NO .....	42
Role of NO in the cardiovascular system .....	42
<i>NO and atrial natriuretic peptide</i> .....	43
<i>NOS in the cardiac myocyte</i> .....	43
<i>NO and the autonomic control of the heart rate</i> .....	44
<i>NO and vascular system</i> .....	45
<i>NO and vasodilatation</i> .....	46
<i>NO and blood pressure</i> .....	47
<i>Role of NO in the plasma compartment</i> .....	47
<i>Measurement of NO as a biomarker of cardiovascular function</i> .....	48
Hemoglobin, oxygen and nitric oxide .....	48
<i>Myoglobin and NO</i> .....	49

NO and pulmonary circulation.....	50
<i>Role of NO in the regulation of hypoxic pulmonary vasoconstriction</i> .....	50
Role of NO in the lymphatic system.....	50
Role of NO in the nervous system .....	51
<i>Neurovascular coupling of COX-2 and nNOS</i> .....	52
<i>Neuroglobin</i> .....	52
<i>NO and blood-brain barrier</i> .....	53
<i>NO as a neurotransmitter</i> .....	53
<i>Role of NO in consciousness</i> .....	53
<i>Role of NO in memory and learning</i> .....	54
<i>Role of NO in synaptic plasticity</i> .....	54
<i>Role of NO in the peripheral nervous system</i> .....	54
Role of NO in the cochlea.....	55
NO and neuroendocrine function.....	55
NO and pregnancy .....	55
Role of NO in penile erection .....	55
Role of NO in immune regulation .....	56
Role of NO in temperature regulation .....	57
Role of NO in gastrointestinal system .....	57
Role of NO in kidney function .....	57
Role of NO in liver.....	58
Role of NO in the skin.....	58
<b>4. Role of NO in Diseases.....</b>	<b>60</b>
<b>Introduction .....</b>	<b>60</b>
Cytotoxicity of reactive nitrogen species .....	60
Peroxynitrite, mitochondria and cell death.....	60
<b>Diseases involving oxidative stress and nitric oxide .....</b>	<b>62</b>
<b>Stress-related disorders .....</b>	<b>63</b>
<b>Role of NO in allergic disorders.....</b>	<b>63</b>
<b>Inflammatory diseases .....</b>	<b>64</b>
<b>Autoimmune disorders.....</b>	<b>64</b>
Role of NO in rheumatoid arthritis.....	65
<b>Role of NO in infections .....</b>	<b>66</b>
NO-mediated cytoprotection in bacteria .....	66
Nanoscale nanoparticle delivery for cutaneous infection .....	67
Leishmaniasis .....	67
Malaria and iNOS polymorphism .....	67
Susceptibility of <i>Mycobacterium leprae</i> to NO .....	68
Role of NO in the treatment of tuberculosis .....	68
Septic shock.....	68
Trypanosomiasis .....	69
Viral infections.....	69
<b>Role of NO in anaphylactic shock .....</b>	<b>70</b>
<b>Role of NO in anemia and hypoxia .....</b>	<b>71</b>
<b>Role of NO in neurological disorders.....</b>	<b>71</b>
Neurodegenerative diseases.....	71
<i>NO-induced mitochondrial dysfunction in neurodegeneration</i> .....	72
<i>White matter disorders</i> .....	72
<i>Amyotrophic lateral sclerosis</i> .....	72
<i>Alzheimer's disease</i> .....	73
<i>Role of NO in pathophysiology of Alzheimer's disease</i> .....	73
<i>Role of ApoE genotype</i> .....	76
<i>Parkinson's disease</i> .....	76
Traumatic brain injury .....	78
Epilepsy.....	79
Stroke .....	79
<i>Pathophysiology of cerebral ischemia</i> .....	79
<i>Role of NO in cerebral ischemia</i> .....	80
<i>eNOS gene polymorphisms as predictor of cerebral aneurysm rupture</i> .....	82
<i>Role of NO in assessment of cerebral and retinal blood flow</i> .....	82
<i>Role of NO in cerebral vasospasm after subarachnoid hemorrhage</i> .....	82
<i>Role of NO in neuroprotection</i> .....	83
<i>Stroke and heart disease</i> .....	83
Role of NO in peripheral neuropathy .....	84
<i>iNOS induction in experimental allergic neuritis</i> .....	84
<i>Role of NO in sciatica</i> .....	84
Role of NO in the pathogenesis of muscular dystrophy.....	84
Role of NO in neurological decompression sickness.....	85
<b>Role of NO in psychiatric disorders .....</b>	<b>85</b>
NO-dysregulation in schizophrenia .....	85

<b>Role of NO in pathomechanism of cardiovascular disorders.....</b>	<b>86</b>
Oxidative stress as a cause of cardiovascular disease .....	86
Role of NO in pathomechanism of cardiovascular diseases.....	86
<i>Role of iNOS in cardiovascular disease.....</i>	<i>87</i>
<i>Role of eNOS in cardiovascular disease.....</i>	<i>87</i>
<i>Role of nNOS in cardiac arrhythmia and sudden death .....</i>	<i>88</i>
<i>Role of NO in atherosclerosis.....</i>	<i>88</i>
<i>Therapeutic stimulation of the nitrate-nitrite-NO pathway .....</i>	<i>90</i>
Role of NO in cardiopulmonary disorders.....	90
Role of NO in disturbances of vasodilation .....	90
<i>Caveolin-1 deficiency impairs NO synthesis and vasodilation .....</i>	<i>91</i>
Role of NO in hypercholesterolemia .....	91
NO and systemic hypertension.....	92
Coronary artery disease.....	93
Role of NO in the pathophysiology of angina pectoris.....	93
Congestive heart failure.....	94
<i>Calcium overload as a cause of heart failure.....</i>	<i>94</i>
<i>NO/redox disequilibrium in the failing heart.....</i>	<i>94</i>
Myocardial ischemia/reperfusion injury .....	95
NO pathway in cardiac hypertrophy.....	96
<b>Role of NO in sickle cell disease.....</b>	<b>97</b>
<b>Role of NO in pulmonary disorders .....</b>	<b>97</b>
Role of NO in the pathophysiology of asthma.....	97
<i>iNOS gene polymorphisms in asthma.....</i>	<i>98</i>
<i>Role of S-nitrosoglutathione in bronchodilation in asthma .....</i>	<i>99</i>
Monitoring of exhaled NO.....	99
Nasal NO as a biomarker of response to rhinosinusitis therapy .....	100
Elevated urinary NO as a biomarker of improved survival in ARDS .....	101
Pulmonary hypertension .....	101
<b>Role of NO in renal disorders .....</b>	<b>102</b>
Role of NOS in diabetic nephropathy .....	102
<b>Role of NO in cancer .....</b>	<b>102</b>
Inflammation, NO and colon cancer.....	103
Tumor hypoxia and NO .....	104
NO and p53 mutations.....	104
NO and matrix metalloproteinase.....	105
Role of NO in angiogenesis in cancer .....	105
<b>Role of NO in diseases of the eye.....</b>	<b>106</b>
Glaucoma .....	106
<b>Role of NO in metabolic disorders.....</b>	<b>106</b>
Metabolic syndrome .....	106
Obesity.....	107
Diabetes mellitus .....	107
<b>Role of NO in gastrointestinal disorders .....</b>	<b>108</b>
Role of L-arginine in intestinal adaptation .....	108
Role of NO in irritable bowel syndrome .....	108
Role of NO in inflammatory bowel diseases .....	108
Role of NO in celiac disease.....	109
Role of NO in diabetic gastroparesis .....	109
<b>NO and diseases of the liver .....</b>	<b>109</b>
Cirrhosis of liver .....	109
Hepatic encephalopathy.....	110
<b>Role of NO in skin disorders.....</b>	<b>110</b>
Role of NO and oxidative stress in the aging skin .....	110
Role of NO in wound healing.....	110
<b>Role of NO in erectile dysfunction.....</b>	<b>111</b>
<b>Role of NO in pain .....</b>	<b>112</b>
NO and pain of spinal cord origin .....	112
NO interaction with other receptors in pain .....	112
nNOS and pain .....	112
Role of NO in various types of pain.....	113
<i>Neuropathic pain.....</i>	<i>113</i>
<i>Role of NO in diabetic neuropathy .....</i>	<i>113</i>
<i>NO in oral and facial pain .....</i>	<i>113</i>
<i>Role of NO in migraine.....</i>	<i>114</i>
<i>Role of NO in osteoarthritis .....</i>	<i>114</i>
<i>NO and Fibromyalgia syndrome .....</i>	<i>115</i>
<i>Role of spinal NO in analgesic action .....</i>	<i>116</i>
<b>Role of NO in nicotine addiction.....</b>	<b>116</b>
<b>Role of NO in carbon monoxide poisoning.....</b>	<b>116</b>
<b>Role of NO in chemically-induced toxicity.....</b>	<b>117</b>

Peroxynitrite and drug-dependent toxicity.....	117
Paraquat neurotoxicity.....	117
<b>Role of NO in radiation damage .....</b>	<b>117</b>

## **5. Pharmacology of Nitric Oxide ..... 120**

### **Introduction .....120**

### **Cytotoxic vs cytoprotective role of NO .....120**

### **Antioxidants .....120**

*Ebselen*..... 121

*Nicaraven* ..... 121

*Nitroxides* ..... 122

Antioxidants in relation to NO..... 122

Nitric oxide as an antioxidant ..... 122

### **NO-related drugs .....123**

Drugs that activate eNOS production..... 125

*Aspirin*..... 125

*Dehydroepiandrosterone*..... 125

Drugs that scavenge free radicals/NO..... 125

*Peroxynitrite scavengers*..... 125

*Ruthenium (III) polyaminocarboxylates*..... 126

*Nitrones*..... 126

Drugs that inhibit NO..... 126

*Ginko biloba* ..... 126

*Epigallocatechin*..... 127

### **Delivery of nitric oxide.....127**

Targeted delivery of NO donors ..... 128

Nitric oxide delivery by encapsulated cells..... 128

NO-lipid combination..... 128

NO-releasing coating to prevent infection of implanted devices..... 129

Nanoparticles for controlled/sustained release of NO ..... 129

*Hydrogel/glass nanoparticles*..... 129

*Delivery of nanoparticles to vascular endothelium for release of NO* ..... 129

*Functionalized inorganic colloidal nanovehicles for NO delivery* ..... 129

Release of NO in tissues by extracorporeal shock wave application..... 130

### **Nitric oxide donors .....130**

Nitroglycerine/glycerine trinitrate..... 130

Isosorbide dinitrate ..... 131

Sodium nitrite ..... 131

Organic nitrites..... 132

NO-releasing NSAIDs ..... 132

COX-inhibiting NO-donors ..... 133

Grafting of NO-releasing structures on to existing drugs ..... 135

Mesoionic Oxatriazoles ..... 136

Cysteine-containing NO donors..... 136

Sodium nitroprusside..... 137

Syndnonimines ..... 137

S-Nitrosothiols..... 137

*Cavosonstat* ..... 138

Diazeniumdiolates..... 138

COX-2 inhibitors ..... 139

NO hydrogels ..... 139

Novel NO donors..... 139

NO mimetics ..... 140

Comparison of classical nitrates, grafted NO donors, and NO mimetics ..... 140

NO donors and soluble guanylate cyclase activation ..... 141

NO donors for increasing the efficacy of chemotherapy ..... 141

### **Factors that enhance availability of NO .....141**

Modulators of cyclic guanosine-3',5'-monophosphate-dependent protein kinases..... 142

### **NOS-modulating drugs.....143**

Drugs that activate eNOS..... 143

*Statins*..... 143

*Angiotensin converting enzyme inhibitors* ..... 144

*17 Beta-estradiol* ..... 144

*C-2431* ..... 144

NOS inhibitors ..... 144

*Rationale of NOS inhibitors*..... 144

*L-Arginine* ..... 146

*Design of NOS inhibitors*..... 146

*Selective iNOS inhibitors*..... 147

*Non-amino acid-based inhibitors*..... 148

*Aminoguanidine*..... 148

Heme ligands .....	149
Pterin antagonists .....	149
Fused-ring bio-isoteric models of arginine as NOS inhibitors .....	149
nNOS inhibitors .....	149
Lubeluzole .....	151
Neurotrophic factors.....	151
Therapies based on action of NOS as a paraquat diaphorase .....	151
Concluding remarks about NOS inhibiting drugs.....	152
<b>NO and stem cell-based therapy .....</b>	<b>152</b>
<b>Nitric oxide and gene therapy.....</b>	<b>153</b>
NOS gene transfer .....	153
Inhibition of NOS by antisense technology .....	154
<b>Drugs that modulate NO action on platelets .....</b>	<b>154</b>
Action of NO and NO donors on platelets.....	155
NOS inhibitors and NO scavengers .....	155
<b>Phosphodiesterase inhibitors.....</b>	<b>155</b>
<b>Activators of soluble guanylate cyclase .....</b>	<b>155</b>
YC-1.....	155
A-350619 .....	156
Cinaciguat.....	156
<b>Secondary role of NO in the action of drugs.....</b>	<b>156</b>
Selective serotonin reuptake inhibitors .....	156
P2Y receptors and NO.....	157
Calcium channel blockers and NO.....	157
Nitric oxide-based transdermal drug delivery.....	157
Mechanism of resistance of NO-based drugs.....	157
<b>NO and nutraceuticals .....</b>	<b>158</b>
Diet and endogenous production of NO .....	158
L-arginine as a nutraceutical .....	159
Nitrate and nitrite .....	159
Oleuropein .....	159
Role of NO in beneficial effects of chocolate.....	159
<b>6. Therapeutic Applications .....</b>	<b>162</b>
<b>Introduction .....</b>	<b>162</b>
<b>Management of pulmonary disorders by NO-based methods .....</b>	<b>162</b>
Manufacture of NO gas for inhalation.....	162
NO gas inhalation systems for pulmonary disorders.....	162
NO inhalation for acute respiratory distress syndrome .....	162
NO inhalation for premature children with pulmonary dysplasia .....	163
NO inhalation for premature children with respiratory failure.....	163
Management of pulmonary hypertension.....	164
NO-based treatment of pulmonary hypertension .....	164
Pediatric pulmonary hypertension .....	164
Gene therapy for pulmonary hypertension.....	166
Clinical trials of NO therapies for pulmonary arterial hypertension .....	166
Management of asthma and COPD .....	167
iNOS inhibitors for asthma .....	167
NO for bronchodilation in asthma.....	167
NO in COPD.....	167
NO-releasing drugs for the treatment of lung infections .....	167
NO for the treatment of pneumonia in COVID-19 .....	168
Role of NO in acute lung injury after smoke inhalation .....	168
<b>Cardiovascular disorders .....</b>	<b>168</b>
Role of NO in cardioprotection .....	169
Role of NO in the management of myocardial infarction .....	170
Role of NO in the management of hypertension .....	171
Role of NO in the management of angina pectoris .....	172
Role of NO in therapy of coronary heart disease.....	172
NO-releasing aspirin in patients undergoing CABG .....	173
Management of coronary restenosis .....	173
Modified NO donors.....	173
NO-generating stent for coronary restenosis.....	173
eNOS gene therapy for restenosis .....	175
NO-based management of cardiac hypertrophy.....	175
Congestive heart failure.....	175
Limitation of antioxidant therapy in congestive heart failure .....	175
NO-based therapies for congestive heart failure.....	176
eNOS gene therapy for congestive heart failure .....	176
Gene transfer of nNOS in congestive heart failure .....	176
NO-based therapy for management of cardiogenic shock .....	177

NO-based therapy for cardiac arrhythmias .....	177
Prophylaxis of cardiovascular disorders .....	177
<i>Prevention of atherosclerosis with aging</i> .....	177
Role of iNO in cardiac surgery .....	178
Strategies for increasing NO signaling in cardiovascular disorders .....	178
Peripheral vascular disorders .....	179
<i>Peripheral atherosclerotic arterial disease</i> .....	179
<i>Peripheral ischemic disease</i> .....	179
<i>An eNOS mutant as therapeutic for peripheral vascular ischemia</i> .....	179
<i>Sodium nitrite therapy for peripheral vascular ischemia</i> .....	180
<i>Raynaud's phenomenon</i> .....	180
<b>Neurological disorders</b> .....	<b>181</b>
Cerebrovascular ischemic disorders .....	181
<i>Attenuation of NO for neuroprotection in cerebral ischemia</i> .....	181
<i>Use of NO donors in cerebral ischemia</i> .....	182
<i>Use of NO donors in cerebral reperfusion injury</i> .....	182
<i>NO-based treatments for cerebral vasospasm due to SAH</i> .....	183
<i>NOS gene therapy for cerebral vasospasm</i> .....	183
Degenerative CNS disorders .....	184
<i>Statins for Alzheimer's disease</i> .....	184
<i>NO mimetics for Alzheimer's disease</i> .....	184
<i>iNOS inhibitors for treatment of Alzheimer's disease</i> .....	185
<i>NO-NSAIDs for Alzheimer's disease</i> .....	185
<i>Ginkgo biloba for Alzheimer's disease</i> .....	185
<i>Personalization of NO-based therapy for Alzheimer's disease</i> .....	185
Role of NO in the treatment of traumatic brain injury .....	186
Neuroinflammatory disorders .....	186
Role of NO-releasing sodium nitroprusside in the treatment of schizophrenia .....	186
Antidepressant effect of NOS inhibitors .....	187
Muscular dystrophy .....	187
Vestibulotoxicity .....	188
NO for opening the blood-brain barrier .....	188
<b>Cochlear disorders</b> .....	<b>189</b>
Cochlear ischemia .....	189
Role of NO in sensoryneural hearing loss .....	189
Ophthalmic disorders .....	189
<i>Glaucoma</i> .....	189
<b>Pain</b> .....	<b>190</b>
NO-based therapies for pain .....	190
Treatment of diabetic neuropathy with isosorbide dinitrate spray .....	190
NO-based therapies for migraine .....	191
NO-based therapy for fibromyalgia syndrome .....	191
<b>NO-based therapies for inflammatory disorders</b> .....	<b>191</b>
<b>NO-based therapies for gastrointestinal disorders</b> .....	<b>191</b>
Protection of gastrointestinal injury from NSAIDs .....	191
Role of NO in the treatment of inflammatory bowel disease .....	192
Topical nitroglycerin for chronic anal fissure .....	192
<b>Cancer</b> .....	<b>193</b>
Mechanism of action of NO in cancer .....	193
Antineoplastic effect of iNOS-expressing cells .....	193
Role of NO in drug resistance of cancer .....	193
Role of NO in treatment of brain tumors .....	194
NO-induced apoptosis .....	194
Role of NO in antiangiogenesis therapies in cancer .....	195
NO donors for the treatment of cancer .....	195
NO-releasing NSAIDs and colon cancer chemoprevention .....	195
Rationale of combining NO aspirin with cancer vaccines .....	196
NO-based cancer gene therapy .....	196
Transdermal nitroglycerine for prostate cancer .....	197
<b>NO-based therapies for skin disorders</b> .....	<b>197</b>
NO-based therapies for skin infections .....	197
Role of NO in the treatment of psoriasis .....	198
<b>NO-based therapy for sickle cell anemia</b> .....	<b>198</b>
Inhaled NO for acute respiratory distress syndrome in sickle cell disease .....	198
NO inhalation for pulmonary hypertension in sickle cell anemia .....	199
<b>Role of NO in disorders associated with pregnancy</b> .....	<b>199</b>
Pre-eclampsia and intra-uterine growth restriction .....	199
Use of NO donors in management of labor .....	200
<b>Erectile dysfunction</b> .....	<b>200</b>
Selective inhibitors of phosphodiesterase 5 .....	200
Erectile dysfunction in diabetes .....	201



NO-donating substances for treatment of ED .....	201
NOS gene transfer for ED .....	202
<b>Organ transplant rejection .....</b>	<b>202</b>
<b>Role of NO in the treatment of renal disorders .....</b>	<b>203</b>
<b>Role of NO in the treatment of hepatic disorders .....</b>	<b>204</b>
Portal hypertension .....	204
NO inhalation for restoration of liver function following transplantation .....	204
<b>Role of NO in blood transfusion .....</b>	<b>205</b>
<b>Role of NO in the treatment of osteoporosis .....</b>	<b>205</b>
<b>NO-based wound healing .....</b>	<b>206</b>
<b>7. Evaluation of NO-Based Drugs .....</b>	<b>208</b>
<b>Current status .....</b>	<b>208</b>
<b>Antioxidant vs. NO-based approaches .....</b>	<b>208</b>
<b>SWOT analysis of selected approaches for NO modulation .....</b>	<b>208</b>
NO donors by grafting of NO-releasing structures .....	208
NOS modulation .....	209
<b>Challenges of developing NO-based therapies .....</b>	<b>210</b>
<b>Concluding remarks and future prospects .....</b>	<b>210</b>
<b>8. Markets for NO-based Therapies .....</b>	<b>212</b>
<b>Introduction .....</b>	<b>212</b>
<b>Impact of NO-based therapies on international markets .....</b>	<b>212</b>
<b>Share of NO-based therapies in major therapeutic areas .....</b>	<b>212</b>
<b>Share of NO-based therapies in cardiovascular disorders .....</b>	<b>213</b>
Hypercholesterolemia .....	213
Myocardial infarction .....	214
Angina pectoris/coronary artery disease .....	214
Heart failure .....	214
Coronary restenosis and stenting .....	214
<b>Strategies for developing NO-based therapy markets .....</b>	<b>214</b>
Addressing the unfulfilled needs .....	215
Multidisciplinary approaches .....	215
Collaboration between the academia and the industry .....	216
Education of the public .....	216
<b>9. Companies .....</b>	<b>218</b>
<b>Introduction .....</b>	<b>218</b>
<b>Profiles of companies with focus on NO .....</b>	<b>220</b>
<b>Major pharmaceutical companies with involvement in NO .....</b>	<b>232</b>
<b>Smaller biotech and pharmaceutical companies involved in NO .....</b>	<b>236</b>
<b>Biopharmaceutical companies involved in antioxidant research .....</b>	<b>246</b>
<b>Companies supplying NO equipment for healthcare .....</b>	<b>250</b>
<b>Academic institutes with commercial collaboration in NO research .....</b>	<b>254</b>
<b>Companies supplying NO products for research .....</b>	<b>255</b>
<b>10. References .....</b>	<b>260</b>

## Tables

Table 1-1: Historical landmarks in the discovery and applications of nitric oxide .....	14
Table 3-1: Important functions of NO in the human body .....	39
Table 4-1: Diseases involving nitric oxide .....	62
Table 4-2: Role of nitric oxide in pathogenesis of autoimmune disorders .....	65
Table 4-3: Role of nitric oxide in infections .....	66
Table 5-1: Neuroprotective antioxidants .....	120
Table 5-2: NO-related drugs .....	123
Table 5-3: Methods of delivery of nitric oxide .....	127
Table 5-4: Comparison of classical nitrates, grafted NO donors, and NO mimetics .....	140
Table 5-5: Classification of NOS inhibitors .....	145
Table 5-6: Potential clinical applications of gene transfer for NOS overexpression .....	153
Table 6-1: Clinical trials of NO-based therapies for pulmonary hypertension .....	166
Table 6-2: Cardiovascular disorders for which NO-based therapies are used .....	169
Table 6-3: Selected neurological applications of NO-based therapies .....	181
Table 6-4: NO-related therapies for pain .....	190
Table 7-1: SWOT of technology – NO donors by grafting of NO-releasing structures .....	209
Table 7-2: SWOT of products – NO donors by grafting of NO-releasing structures .....	209
Table 7-3: SWOT of NOS gene manipulation .....	209
Table 7-4: SWOT of analgesic development by NOS isoform targeting .....	210

Table 8-1: Share of NO-based therapies in relevant therapeutic areas 2020-2030 .....	213
Table 8-2: Share of NO-based therapies in cardiovascular diseases 2020-2030 .....	213
Table 9-1: Classification of companies involved in NO and antioxidant therapies.....	219
Table 9-2: NicOx products in development.....	223
Table 9-3: NO-related products of Sigma Aldrich .....	257
Table 9-4: Collaborations of companies relevant to nitric oxide.....	259

## Figures

Figure 1-1: Nitrogen cycle in the human body .....	16
Figure 1-2: Biosynthesis of nitric oxide (NO) .....	18
Figure 1-3: NO synthase pathway.....	19
Figure 2-1: Reactivity of nitric oxide with heme proteins in oxygen or peroxide reaction cycles.....	28
Figure 2-2: NO-cGMP pathway leading to vasorelaxation .....	29
Figure 2-3: The biological pathways toward protein nitration.....	31
Figure 2-4: NF- $\kappa$ B activation and iNOS induction.....	32
Figure 2-5: Overview of mitochondrial NO-cytochrome c oxidase signaling pathway.....	34
Figure 3-1: Role of NO in adaptation to high altitude .....	38
Figure 3-2: NOS in the cardiac myocyte .....	44
Figure 3-3: Pathways for generation and inhibition of NO in the vasculature.....	45
Figure 3-4: Interactions of the Mb compounds with O <sub>2</sub> and NO .....	49
Figure 3-5: Role of NO in dynamics of lymphatic pumping .....	51
Figure 4-1: Molecular mechanisms of peroxynitrite-mediated cell death.....	61
Figure 4-2: NO neurotoxicity and neuroprotection in relation to Alzheimer's disease.....	75
Figure 4-3: Some steps in the ischemic cascade and site of action of neuroprotectives .....	80
Figure 4-4: Dual role of nitric oxide (NO) in cerebral ischemia .....	81
Figure 4-5: Blood cell-endothelial cell interactions induced by hypercholesterolemia.....	91
Figure 4-6: Effects of NO on the pathophysiology of myocardial ischemia-reperfusion .....	96
Figure 4-7: Nitric oxide: tumor enhancement or inhibition .....	102
Figure 4-8: Role of nitric oxide in angiogenesis.....	105
Figure 4-9: Role of NO in HBO-induced wound healing .....	111
Figure 5-1: Nitrogen oxide mimetics – synergy by chemical modification .....	140
Figure 5-2: Factors that enhance availability of NO .....	142
Figure 5-3: Mechanism of resistance to NO-based therapeutics .....	158
Figure 5-4: Effect of dietary trigonelline on NO production of NO in vascular endothelium.....	158
Figure 6-1: Mechanism of development of tolerance to glyceryl trinitrate.....	171
Figure 6-2: Vicious circle of vascular occlusion following angioplasty and stenting.....	174
Figure 6-3: PDE5 inhibition and the response to sexual stimulation .....	201
Figure 8-1: Unfulfilled needs in NO therapeutics .....	215